It's also my belief that they partner RSV - either for a good amount of money if HR data is strong and a clear path to a phase 3 soon, or a small amount for both compounds w more of the value in 323 and later milestones
I actually think they planned the late Q3 data release even though they could easily have top lined data a month earlier to concurrently announce a partnership, either on very nice terms w strong data, or a modest sum to offload the programs and fully transform the focus to immunology
Market Data 
Markets 
AI
